drugset / Trial / NCT04278898
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose
Phase 2
Recruiting
24 enrolled
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC.
Timeline
- Start
- 2021-02-12
- Primary completion
- 2028-07-31
- Completion
- 2029-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 2700 mg | Oral |